India's Caplin Point Laboratories soars after Q3 profit, says no impact from coronavirus

Caplin Point Laboratories

05/02/2020 08:10

** Indian pharmaceutical company's shares  CAPL.NS  jump as
much as 15.5% to 312.50 rupees; biggest intraday pct jump since
July 5, 2017
    ** CAPL posts ~28% rise in December-quarter consolidated net
profit to 585.6 mln rupees ($8.22 mln)  urn:newsml:reuters.com:*:nFWN2A412E
    ** "Coronavirus situation in China has no impact on
operations, as Company's main suppliers in Shijiazhuang have
continued production without stoppage," company says (http://bit.ly/3b95p1w)
    ** CAPL says Q3 consol revenue from ops was 2.28 bln rupees
vs 1.59 bln rupees a yr earlier 
    ** China's National Health Commission said another 65 deaths
were reported on Tuesday from the ongoing coronavirus outbreak,
bringing the toll to 490  urn:newsml:reuters.com:*:nL4N2A50AN
    ** CAPL stock fell 21.2% in 2019, underperforming the ~9.3%
fall in Nifty Pharma index  .NIPHARM   

 ($1 = 71.2625 Indian rupees)

 (Reporting by Anuron Kumar Mitra in Bengaluru)
 ((AnuronKumar.Mitra@thomsonreuters.com; outside U.S. +91 99863
58469;))